Research programme: heart disorder therapies - Berlin Cures
Alternative Names: BC-00xLatest Information Update: 20 Sep 2024
At a glance
- Originator Berlin Cures
- Class Antiarrhythmics; Heart failure therapies; Nucleotide aptamers
- Mechanism of Action Autoantibody inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Bradycardia; Heart failure
Most Recent Events
- 29 Aug 2024 Early research in Bradycardia in Germany (Parenteral) (Berlin Cures pipeline, August 2024)
- 29 Aug 2024 Early research in Heart failure in Germany (Parenteral) (Berlin Cures pipeline, August 2024)